simendan has been researched along with ramipril in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Akhtar, M; Akhtar, MS; Ali, J; Ansari, SH; Hassan, Q; Najmi, AK; Pillai, KK | 1 |
| Afzal, O; Akhtar, MS; Altamimi, A; Hassan, MZ; Hassan, Q; Mohammad, AAS; Sharma, AK; Tabassum, F | 1 |
2 other study(ies) available for simendan and ramipril
| Article | Year |
|---|---|
Levosimendan suppresses oxidative injury, apoptotic signaling and mitochondrial degeneration in streptozotocin-induced diabetic cardiomyopathy.
Topics: Animals; Apoptosis; C-Reactive Protein; Cardiotonic Agents; Caspase 3; Diabetes Mellitus, Experimental; Diabetic Cardiomyopathies; Glutathione Peroxidase; Hydrazones; Hypoglycemic Agents; Insulin; Male; Malondialdehyde; Oxidative Stress; Pyridazines; Ramipril; Rats; Rats, Wistar; Simendan; Superoxide Dismutase; Tumor Necrosis Factor-alpha | 2016 |
Comparative Efficacy of Levosimendan, Ramipril, and Sacubitril/ Valsartan in Isoproterenol-induced Experimental Heart Failure: A Hemodynamic and Molecular Approach.
Topics: Antioxidants; Calcium; Collagen; Heart Failure; Hemodynamics; Humans; Isoproterenol; Myocardial Infarction; Ramipril; Simendan; Valsartan | 2023 |